ClinicalTrials.gg
CompletedNCT01160744Updated Sep 13, 2019Results posted

A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of IMC-1121B (ramucirumab) and Pemetrexed in Carcinoma, Non-Small-Cell Lung, sponsored by Eli Lilly and Company. Completed at 53 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-13.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 9 under way, 2 of them phase 3. Ramucirumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
4th of 24
280 · median 74
Started
2010
with 1 other
Phase 2
14 of 24
1 open now
Registered
2nd of 24
by date
Lead sponsor
10 of 24
Eli Lilly and Company

Among the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung, this one is the 4th largest by enrollment, is one of 2 that started in 2010, is one of 14 in phase 2, and was the 2nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ramucirumab

Ramucirumab: first FDA approval 2014 (CYRAMZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to determine if participants with Stage IV NSCLC have a better outcome when treated with IMC-1121B in combination with pemetrexed + carboplatin/cisplatin or gemcitabine + carboplatin/cisplatin than when treated with pemetrexed + carboplatin/cisplatin or gemcitabine + carboplatin/cisplatin alone.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung

Keywords

  • Lung neoplasms
  • Lung cancer
  • Non-small Cell Lung Cancer
  • pemetrexed
  • squamous
  • nonsquamous
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed NSCLC
  • Stage IV disease at the time of study entry
  • at the time of study entry
  • Resolution to Grade ≤ 1 Adverse Events, of all toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy (except alopecia)
  • Adequate hematologic function, hepatic function, renal function and coagulation function
  • If sexually active, must be , surgically sterile, or using effective ; and agrees to use adequate contraception during the study period and for up to 6 months after the last dose of study medication
  • Female participants of must have a negative serum pregnancy test

Exclusion criteria

Exclusion Criteria:

  • Has cirrhosis at a level of B (or worse), or cirrhosis and a history of hepatic encephalopathy, or ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis
  • Tumor wholly or partially contains small cell lung cancer
  • Untreated central nervous system (CNS) , eligible if they are clinically stable with regard to neurologic function, off all after cranial irradiation at least 2 weeks prior or after surgical resection performed at least 4 weeks prior to randomization
  • Concurrent active other than adequately treated basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix. A participant with previous history of malignancy other than NSCLC is eligible, provided that he/she has been free of disease for ≥ 3 years
  • Received prior therapy with monoclonal antibodies, signal transduction inhibitors, or any therapies targeting the vascular endothelial growth factor (VEGF) or vascular endothelial growth factor receptor (VEGFR)
  • Receiving concurrent treatment with other anticancer therapy
  • Has received previous chemotherapy for Stage IV NSCLC (participants who have received chemotherapy are eligible if the last administration of the prior adjuvant regimen occurred at least 6 months prior to randomization)
  • Has radiologically documented evidence of major blood vessel invasion or encasement by cancer
  • Has undergone chest irradiation within 12 weeks prior to randomization (except palliative irradiation of bone lesions)
  • Ongoing or active infection
  • History of significant neurological or psychiatric disorders
  • Experienced coronary artery disease, myocardial infarction within 6 months prior to randomization, uncontrolled congestive heart failure, or symptomatic poorly controlled arrhythmia
  • Poorly-controlled hypertension
  • Experienced any serious Grade 3-4 gastrointestinal bleeding within 3 months prior to study entry
  • Receiving chronic daily treatment with aspirin (> 325 mg/day) or other known inhibitors of function
  • Serious nonhealing wound, ulcer, or bone fracture within 28 days prior to randomization
  • Major surgery within 28 days prior the first dose of study medication, or subcutaneous venous access device placement within 7 days prior to randomization
  • Elective or a planned major surgery
  • Pregnant or lactating
  • Any other serious uncontrolled medical disorders or psychological conditions
  • Allergy / history of reaction to any of the treatment components
  • History of drug abuse
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
280 participants (actual)

Study arms

  • Experimental
    IMC-1121B + Pemetrexed + Carboplatin (AUC 6) or Cisplatin

    IMC-1121B + Pemetrexed + Carboplatin \[Area Under the Concentration Time Curve 6 (AUC 6)\] or Cisplatin

    Biological: IMC-1121B (ramucirumab) · Drug: Pemetrexed · Drug: Carboplatin (AUC 6) · Drug: Cisplatin

  • Active comparator
    Pemetrexed + Carboplatin (AUC 6) or Cisplatin

    Pemetrexed + Carboplatin (AUC 6) or Cisplatin

    Drug: Pemetrexed · Drug: Carboplatin (AUC 6) · Drug: Cisplatin

  • Experimental
    IMC-1121B + Gemcitabine + Carboplatin (AUC 5) or Cisplatin

    IMC-1121B + Gemcitabine + Carboplatin \[Area Under the Concentration Time Curve 5 (AUC 5)\] or Cisplatin

    Biological: IMC-1121B (ramucirumab) · Drug: Cisplatin · Drug: Gemcitabine · Drug: Carboplatin (AUC 5)

  • Active comparator
    Gemcitabine + Carboplatin (AUC 5) or Cisplatin

    Gemcitabine + Carboplatin (AUC 5) or Cisplatin

    Drug: Cisplatin · Drug: Gemcitabine · Drug: Carboplatin (AUC 5)

Interventions

  • 10 milligrams/kilogram (mg/kg) once every 3 weeks beginning Day 1, Cycle 1

    Also known as: ramucirumab, IMC-1121B, LY3009806

  • 500 milligrams/square meter (mg/m²) on Day 1 of every 21-day cycle

  • Day 1 of every 21-day cycle

  • 75 mg/m² intravenous (IV) on Day 1 of each 21-day cycle

  • 1000 mg/m² on Days 1 and 8 of every 21-day cycle

  • Day 1 of every 21-day cycle

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS was the time from randomization to the first objective progression as defined by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v 1.1) or death from any cause, whichever occurred first. Progressive disease (PD) was defined as ≥20% increase in sum of diameter (SOD) of target lesions and short axes of target lymph nodes, taking as reference the smallest sum of the longest diameters recorded since treatment started and an absolute increase in sum diameter of ≥5 millimeters (mm); appearance of ≥1 new lesions and/or unequivocal progression of existing non-target lesions. Participants alive and without disease progression were censored at the time of the last objective tumor assessment. Participants who did not progress and were lost to follow-up were censored at their last radiographic assessment. If no baseline or post baseline radiologic assessments were available, participants were censored at date of randomization.

    Time frame: Randomization to PD or death (up to 24 months)

Secondary outcomes

  1. Percentage of Participants With Best Overall Response of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]

    Best overall response of CR or PR was defined using RECIST v 1.1 criteria. CR was defined as the disappearance of all lesions, pathological lymph node reduction in short axis to \<10 mm, and normalization of tumor marker levels of non-target lesions. PR was defined as ≥30% decrease in SOD of target lesions taking as reference the baseline sum diameter. PD was defined as ≥20% increase in SOD of target lesions and short axes of target lymph nodes, taking as reference the smallest sum of the longest diameters recorded since treatment started and an absolute increase in sum diameter of ≥5 mm; appearance of ≥1 new lesions and/or unequivocal progression of existing non-target lesions. Participants who had no post baseline tumor assessments were considered non-responders and included in the denominator when calculating response rate. Percentage of participants=(number of participants with CR+PR/total number of participants)\*100.

    Time frame: Day 1, Cycle 1 (3-week cycles) and every 6 weeks thereafter to PD (up to 24 months)

  2. Overall Survival (OS)

    OS was defined as the time from the date of randomization to the date of death from any cause. If the participant was alive at the end of the follow-up period or was lost to follow-up, OS was censored on the last date the participant was known to be alive.

    Time frame: Randomization to the date of death from any cause (up to 31.3 months)

  3. Duration of Response (DOR)

    DOR was measured from the time criteria were met for the first objectively recorded CR or PR until the first date criteria for PD were met or death. Response was defined using RECIST v 1.1 criteria. CR was defined as the disappearance of all lesions, pathological lymph node reduction in short axis to \<10 mm, and normalization of tumor marker level of non-target lesions. PR was defined as ≥30% decrease SOD of target lesions taking as reference the baseline sum diameter. PD was defined as ≥20% increase in SOD of target lesions and short axes of target lymph nodes, taking as reference the smallest sum of the longest diameters recorded since treatment started and an absolute increase in sum diameter of ≥5 mm; appearance of ≥1 new lesions and/or unequivocal progression of existing non-target lesions. Participants who did not relapse were censored at the day of their last objective tumor assessment.

    Time frame: Time of first response (CR or PR) until PD or death (up to 24 months)

  4. Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Who Died

    Data presented are the number of participants with at least 1 treatment-emergent adverse event (TEAE) and treatment-emergent serious adverse event (SAE), as well as, the number of participants who died during the study. TEAEs were defined as serious and other non-serious AEs that occurred or worsened after study treatment (regardless of causality). A summary of SAEs and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: Day 1, Cycle 1 (3-week cycles) Up to 3 Years

Other outcomes

  1. Percentage of Participants With CR, PR, or Stable Disease (SD) [Disease Control Rate (DCR)]

    DCR: percentage of participants with CR, PR, or SD using RECIST v 1.1 criteria. CR: disappearance of all lesions, pathological lymph node reduction in short axis to \<10 mm, and normalization of tumor marker levels of non-target lesions. PR: ≥30% decrease in SOD of target lesions taking as reference baseline sum diameter. PD: ≥20% increase in SOD of target lesions and short axes of target lymph nodes, taking as reference smallest sum of longest diameters recorded since treatment started and an absolute increase in sum diameter ≥5 mm; appearance of ≥1 new lesions and/or unequivocal progression of existing non-target lesions. SD: neither sufficient shrinkage to qualify for PR nor increase to qualify for PD. Participants who had no post baseline tumor assessments were considered non-responders and included in the denominator when calculating response rate. Percentage of participants=(number of participants with CR+PR+SD/total number of participants)\*100.

    Time frame: Day 1, Cycle 1 (3-week cycles) and every 6 weeks thereafter to PD (up to 24 months)

  2. Change in Tumor Size (CTS)

    CTS was defined as the log ratio of tumor size at 6 weeks to tumor size at baseline. CTS at 6 weeks=Log (Sum of Target Lesion Measurements at 6 Weeks)-Log (Sum of Target Lesion Measurements at Baseline).

    Time frame: Baseline, 6 weeks

07

Results

Posted Dec 29, 2014

Participant flow

Participant flow — Overall Study
MilestonePem + Carb or Cis (Non-Squamous)Ram + Pem + Carb or Cis (Non-Squamous)Gem + Carb or Cis (Squamous)Ram + Gem + Carb or Cis (Squamous)
Started71696971
Received study drug69676371
Completed60646267
Not completed11574
Withdrew: Withdrawal by subject11564
Withdrew: Not meet inclusion/exclusion criteria0010

Outcome measures

PrimaryProgression-Free Survival (PFS)

PFS was the time from randomization to the first objective progression as defined by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v 1.1) or death from any cause, whichever occurred first. Progressive disease (PD) was defined as ≥20% increase in sum of diameter (SOD) of target lesions and short axes of target lymph nodes, taking as reference the smallest sum of the longest diameters recorded since treatment started and an absolute increase in sum diameter of ≥5 millimeters (mm); appearance of ≥1 new lesions and/or unequivocal progression of existing non-target lesions. Participants alive and without disease progression were censored at the time of the last objective tumor assessment. Participants who did not progress and were lost to follow-up were censored at their last radiographic assessment. If no baseline or post baseline radiologic assessments were available, participants were censored at date of randomization.

Time frame:
Randomization to PD or death (up to 24 months)
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsPem + Carb or Cis (Non-Squamous)Ram + Pem + Carb or Cis (Non-Squamous)Gem + Carb or Cis (Squamous)Ram + Gem + Carb or Cis (Squamous)
Progression-Free Survival (PFS)5.6 (4.0 to 5.7)7.2 (5.8 to 8.4)5.4 (4.7 to 5.7)5.6 (4.4 to 6.0)
Statistical analysis
  • Pem + Carb or Cis (Non-Squamous) vs Ram + Pem + Carb or Cis (Non-Squamous) · Log Rank · p = 0.1318 · Hazard ratio (hr): 0.75 · 90% CI 0.55 to 1.03
  • Gem + Carb or Cis (Squamous) vs Ram + Gem + Carb or Cis (Squamous) · Log Rank · p = 0.5215 · Hazard ratio (hr): 0.88 · 90% CI 0.64 to 1.22
SecondaryPercentage of Participants With Best Overall Response of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]

Best overall response of CR or PR was defined using RECIST v 1.1 criteria. CR was defined as the disappearance of all lesions, pathological lymph node reduction in short axis to \<10 mm, and normalization of tumor marker levels of non-target lesions. PR was defined as ≥30% decrease in SOD of target lesions taking as reference the baseline sum diameter. PD was defined as ≥20% increase in SOD of target lesions and short axes of target lymph nodes, taking as reference the smallest sum of the longest diameters recorded since treatment started and an absolute increase in sum diameter of ≥5 mm; appearance of ≥1 new lesions and/or unequivocal progression of existing non-target lesions. Participants who had no post baseline tumor assessments were considered non-responders and included in the denominator when calculating response rate. Percentage of participants=(number of participants with CR+PR/total number of participants)\*100.

Time frame:
Day 1, Cycle 1 (3-week cycles) and every 6 weeks thereafter to PD (up to 24 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Best Overall Response of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]
percentage of participantsPem + Carb or Cis (Non-Squamous)Ram + Pem + Carb or Cis (Non-Squamous)Gem + Carb or Cis (Squamous)Ram + Gem + Carb or Cis (Squamous)
Percentage of Participants With Best Overall Response of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]38.049.324.646.5
Statistical analysis
  • Pem + Carb or Cis (Non-Squamous) vs Ram + Pem + Carb or Cis (Non-Squamous) · Chi-squared · p = 0.1797 · Odds ratio (or): 1.58 · 90% CI 0.90 to 2.78
  • Gem + Carb or Cis (Squamous) vs Ram + Gem + Carb or Cis (Squamous) · Chi-squared · p = 0.0070 · Odds ratio (or): 2.66 · 90% CI 1.45 to 4.86
SecondaryOverall Survival (OS)

OS was defined as the time from the date of randomization to the date of death from any cause. If the participant was alive at the end of the follow-up period or was lost to follow-up, OS was censored on the last date the participant was known to be alive.

Time frame:
Randomization to the date of death from any cause (up to 31.3 months)
Reported as:
Median · months
Overall Survival (OS)
monthsPem + Carb or Cis (Non-Squamous)Ram + Pem + Carb or Cis (Non-Squamous)Gem + Carb or Cis (Squamous)Ram + Gem + Carb or Cis (Squamous)
Overall Survival (OS)10.4 (8.2 to 15.9)13.9 (10.0 to 17.8)11.3 (9.7 to 13.3)10.4 (7.8 to 14.8)
Statistical analysis
  • Pem + Carb or Cis (Non-Squamous) vs Ram + Pem + Carb or Cis (Non-Squamous) · Log Rank · p = 0.8916 · Hazard ratio (hr): 1.03 · 90% CI 0.74 to 1.42
  • Gem + Carb or Cis (Squamous) vs Ram + Gem + Carb or Cis (Squamous) · Log Rank · p = 0.6847 · Hazard ratio (hr): 0.93 · 90% CI 0.68 to 1.27
SecondaryDuration of Response (DOR)

DOR was measured from the time criteria were met for the first objectively recorded CR or PR until the first date criteria for PD were met or death. Response was defined using RECIST v 1.1 criteria. CR was defined as the disappearance of all lesions, pathological lymph node reduction in short axis to \<10 mm, and normalization of tumor marker level of non-target lesions. PR was defined as ≥30% decrease SOD of target lesions taking as reference the baseline sum diameter. PD was defined as ≥20% increase in SOD of target lesions and short axes of target lymph nodes, taking as reference the smallest sum of the longest diameters recorded since treatment started and an absolute increase in sum diameter of ≥5 mm; appearance of ≥1 new lesions and/or unequivocal progression of existing non-target lesions. Participants who did not relapse were censored at the day of their last objective tumor assessment.

Time frame:
Time of first response (CR or PR) until PD or death (up to 24 months)
Reported as:
Median · months
Duration of Response (DOR)
monthsPem + Carb or Cis (Non-Squamous)Ram + Pem + Carb or Cis (Non-Squamous)Gem + Carb or Cis (Squamous)Ram + Gem + Carb or Cis (Squamous)
Duration of Response (DOR)4.5 (3.1 to 5.7)5.5 (4.4 to 5.8)4.3 (4.2 to 5.5)4.3 (3.3 to 5.6)
SecondaryNumber of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Who Died

Data presented are the number of participants with at least 1 treatment-emergent adverse event (TEAE) and treatment-emergent serious adverse event (SAE), as well as, the number of participants who died during the study. TEAEs were defined as serious and other non-serious AEs that occurred or worsened after study treatment (regardless of causality). A summary of SAEs and other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
Day 1, Cycle 1 (3-week cycles) Up to 3 Years
Reported as:
Count of participants · Participants
Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Who Died
ParticipantsPem + Carb or Cis (Non-Squamous)Ram + Pem + Carb or Cis (Non-Squamous)Gem + Carb or Cis (Squamous)Ram + Gem + Carb or Cis (Squamous)
Treatment-Emergent SAE38442939
Treatment-Emergent Adverse Event68676371
Deaths51555556
Other pre-specifiedPercentage of Participants With CR, PR, or Stable Disease (SD) [Disease Control Rate (DCR)]

DCR: percentage of participants with CR, PR, or SD using RECIST v 1.1 criteria. CR: disappearance of all lesions, pathological lymph node reduction in short axis to \<10 mm, and normalization of tumor marker levels of non-target lesions. PR: ≥30% decrease in SOD of target lesions taking as reference baseline sum diameter. PD: ≥20% increase in SOD of target lesions and short axes of target lymph nodes, taking as reference smallest sum of longest diameters recorded since treatment started and an absolute increase in sum diameter ≥5 mm; appearance of ≥1 new lesions and/or unequivocal progression of existing non-target lesions. SD: neither sufficient shrinkage to qualify for PR nor increase to qualify for PD. Participants who had no post baseline tumor assessments were considered non-responders and included in the denominator when calculating response rate. Percentage of participants=(number of participants with CR+PR+SD/total number of participants)\*100.

Time frame:
Day 1, Cycle 1 (3-week cycles) and every 6 weeks thereafter to PD (up to 24 months)
Reported as:
Number · percentage of participants
Percentage of Participants With CR, PR, or Stable Disease (SD) [Disease Control Rate (DCR)]
percentage of participantsPem + Carb or Cis (Non-Squamous)Ram + Pem + Carb or Cis (Non-Squamous)Gem + Carb or Cis (Squamous)Ram + Gem + Carb or Cis (Squamous)
Percentage of Participants With CR, PR, or Stable Disease (SD) [Disease Control Rate (DCR)]70.4 (61.5 to 79.3)85.5 (78.5 to 92.5)66.7 (57.3 to 76.0)73.2 (64.6 to 81.9)
Statistical analysis
  • Pem + Carb or Cis (Non-Squamous) vs Ram + Pem + Carb or Cis (Non-Squamous) · Chi-squared · p = 0.0316 · Odds ratio (or): 2.48 · 90% CI 1.22 to 5.02
  • Gem + Carb or Cis (Squamous) vs Ram + Gem + Carb or Cis (Squamous) · Chi-squared · p = 0.3962 · Odds ratio (or): 1.37 · 90% CI 0.74 to 2.52
Other pre-specifiedChange in Tumor Size (CTS)

CTS was defined as the log ratio of tumor size at 6 weeks to tumor size at baseline. CTS at 6 weeks=Log (Sum of Target Lesion Measurements at 6 Weeks)-Log (Sum of Target Lesion Measurements at Baseline).

Time frame:
Baseline, 6 weeks
Reported as:
Mean · log ratio
Change in Tumor Size (CTS)
log ratioPem + Carb or Cis (Non-Squamous)Ram + Pem + Carb or Cis (Non-Squamous)Gem + Carb or Cis (Squamous)Ram + Gem + Carb or Cis (Squamous)
Change in Tumor Size (CTS)-0.2 ± 0.23-0.2 ± 0.22-0.3 ± 0.31-0.4 ± 0.39
Statistical analysis
  • Pem + Carb or Cis (Non-Squamous) vs Ram + Pem + Carb or Cis (Non-Squamous) · t-test, 2 sided · p = 0.1571
  • Gem + Carb or Cis (Squamous) vs Ram + Gem + Carb or Cis (Squamous) · t-test, 2 sided · p = 0.1597

Adverse events

Collected over Baseline through Study Completion (Up To 3 Years).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pem + Carb or Cis (Non-Squamous)51/69 (73.9%)38/69 (55.1%)67/69 (97.1%)
Ram + Pem + Carb or Cis (Non-Squamous)55/67 (82.1%)44/67 (65.7%)66/67 (98.5%)
Gem + Carb or Cis (Squamous)55/63 (87.3%)29/63 (46%)62/63 (98.4%)
Ram + Gem + Carb or Cis (Squamous)56/71 (78.9%)39/71 (54.9%)71/71 (100%)
Most frequent serious events
Showing 10 of 138
Most frequent serious events
EventPem + Carb or Cis (Non-Squamous)Ram + Pem + Carb or Cis (Non-Squamous)Gem + Carb or Cis (Squamous)Ram + Gem + Carb or Cis (Squamous)
ThrombocytopeniaBlood and lymphatic system disorders2/694/672/638/71
PneumoniaInfections and infestations6/691/676/637/71
DyspnoeaRespiratory, thoracic and mediastinal disorders1/692/672/636/71
NauseaGastrointestinal disorders4/695/672/630/71
VomitingGastrointestinal disorders4/695/671/630/71
Accidental overdoseInjury, poisoning and procedural complications0/695/670/630/71
AnaemiaBlood and lymphatic system disorders1/691/672/635/71
UnderdoseInjury, poisoning and procedural complications2/694/670/630/71
DehydrationMetabolism and nutrition disorders2/694/671/633/71
NeutropeniaBlood and lymphatic system disorders1/692/670/634/71
Most frequent other events
Showing 10 of 83
Most frequent other events
EventPem + Carb or Cis (Non-Squamous)Ram + Pem + Carb or Cis (Non-Squamous)Gem + Carb or Cis (Squamous)Ram + Gem + Carb or Cis (Squamous)
NeutropeniaBlood and lymphatic system disorders17/6922/6735/6352/71
FatigueGeneral disorders43/6944/6734/6339/71
AnaemiaBlood and lymphatic system disorders37/6932/6740/6338/71
NauseaGastrointestinal disorders39/6935/6736/6327/71
ThrombocytopeniaBlood and lymphatic system disorders15/6922/6727/6336/71
VomitingGastrointestinal disorders24/6922/6712/6318/71
Decreased appetiteMetabolism and nutrition disorders18/6920/6715/6324/71
ConstipationGastrointestinal disorders21/6919/6721/6318/71
DiarrhoeaGastrointestinal disorders19/6919/6712/639/71
HeadacheNervous system disorders8/6919/675/6314/71

Baseline characteristics

All randomized participants.

Age, Customized
Age, Customized(Participants)Pem + Carb or Cis (Non-Squamous)Ram + Pem + Carb or Cis (Non-Squamous)Gem + Carb or Cis (Squamous)Ram + Gem + Carb or Cis (Squamous)Total
<=18 years00000
Between 18 and 65 years37372734135
>=65 years34324037143
Missing Data00202
Sex: Female, Male
Sex: Female, Male(Participants)Pem + Carb or Cis (Non-Squamous)Ram + Pem + Carb or Cis (Non-Squamous)Gem + Carb or Cis (Squamous)Ram + Gem + Carb or Cis (Squamous)Total
Female26332616101
Male45364355179
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pem + Carb or Cis (Non-Squamous)Ram + Pem + Carb or Cis (Non-Squamous)Gem + Carb or Cis (Squamous)Ram + Gem + Carb or Cis (Squamous)Total
Hispanic or Latino14106
Not Hispanic or Latino70656871274
Unknown or Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pem + Carb or Cis (Non-Squamous)Ram + Pem + Carb or Cis (Non-Squamous)Gem + Carb or Cis (Squamous)Ram + Gem + Carb or Cis (Squamous)Total
White65606567257
Black281415
Asian41106
Other00202
Region of Enrollment
Region of Enrollment(Participants)Pem + Carb or Cis (Non-Squamous)Ram + Pem + Carb or Cis (Non-Squamous)Gem + Carb or Cis (Squamous)Ram + Gem + Carb or Cis (Squamous)Total
United States71694241223
Canada00415
Belgium00549
Poland0041216
Germany0014822
United Kingdom00055
08

Study locations

53 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Scottsdale, Arizona 85258, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tucson, Arizona 85704, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Corona, California 92879, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fountain Valley, California 92708, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Riverside, California 92501, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aurora, Colorado 80045, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fort Myers, Florida 33916, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Miami, Florida 33176, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chicago, Illinois 60612, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Peoria, Illinois 61615, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Louisville, Kentucky 40202, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Alexandria, Louisiana 71301, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Minneapolis, Minnesota 55404, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Columbia, Missouri 65201, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lincoln, Nebraska 68506, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Neptune, New Jersey 07754, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bronx, New York 10467, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Latham, New York 12110, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Langhorne, Pennsylvania 19047, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hilton Head Island, South Carolina 29926, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nashville, Tennessee 37203, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bedford, Texas 76022, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dallas, Texas 75231, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    El Paso, Texas 79915, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fort Worth, Texas 76104, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kerrville, Texas 78028, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Longview, Texas 75601, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    McAllen, Texas 78503, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Midland, Texas 79701, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paris, Texas 75460, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Antonio, Texas 78229, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    The Woodlands, Texas 77380, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tyler, Texas 75702, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Waco, Texas 76712, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Christiansburg, Virginia 24073, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fairfax, Virginia 22031, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seattle, Washington 98133, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Spokane Valley, Washington 99216, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gent, 9000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toronto, Ontario M4N 3M5, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Montreal, Quebec H2L 4M1, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Berlin, 14165, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Erlangen, 91054, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Großhansdorf, 22927, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hemer, 58675, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Karlsruhe, 76137, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Regensburg, 93053, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ulm, 89081, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gdansk, 80-952, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Olsztyn, 10-357, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warsaw, 02-781, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bangor, Gwynedo LL57 2PW, United Kingdom
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nottingham, Nottinghamshire NG5 1PB, United Kingdom
09

References and documents

Publications

  • Doebele RC, Spigel D, Tehfe M, Thomas S, Reck M, Verma S, Eakle J, Bustin F, Goldschmidt J Jr, Cao D, Alexandris E, Yurasov S, Camidge DR, Bonomi P. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer. 2015 Mar 15;121(6):883-92. doi: 10.1002/cncr.29132. Epub 2014 Nov 6. PubMed 25377507 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Jan 2014 and a completion of Apr 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2014, 11 months after primary completion. A results delay was requested in May 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2010
First posted
Jul 12, 2010
Start
Sep 2010
Primary completionActual
Jan 2014
CompletionActual
Apr 2018
Results delay requested
May 1, 2014
Results first posted
Dec 29, 2014
Last update
Sep 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01160744
Responsible party
Sponsor
First posted
Jul 12, 2010
Start date
Sep 2010
Primary completion
Jan 2014
Completion
Apr 2018
Results posted
Dec 29, 2014
Last update
Sep 13, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ramucirumab · Pemetrexed · Carboplatin · Gemcitabine

Start the discussion